Wuhan Hvsen Biotechnology Co.,Ltd. (SZSE: 300871)
Health Care · Pharmaceuticals · CN
CN¥23.34
-4.23% today · -1.7% 1Y
Wuhan Hvsen Biotechnology Co.,Ltd. (SZSE: 300871) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $700.59M and employs 1,133 people.
Over the last twelve months the share price has lost 1.7%, trading between 19.08 and 32.62.
Tweenvest scores Wuhan Hvsen Biotechnology Co.,Ltd. across four factors: quality 71/100, value 69/100, growth 47/100, dividend 33/100. Its strongest factor is quality.
300871 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $700.59M
- Revenue (TTM)
- $253.79M
- P/E
- 14.26
- EPS
- 1.64
- Dividend yield
- 1.71%
- Beta (5Y)
- 0.58
- 52-week high
- CN¥32.62
- 52-week low
- CN¥19.08
- Avg volume (3M)
- —
- Shares outstanding
- 201.78M
- Employees
- 1,133
- Next earnings
- —
About Wuhan Hvsen Biotechnology Co.,Ltd.
Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.
- ISIN
- CNE1000047H6
- Founded
- 2002
- Listed since
- Aug 24, 2020
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.